Dosulepine-escitalopram

From Psychiatrienet
Revision as of 14:24, 5 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram

Switch medication from dosulepine to escitalopram.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Before day 1: gradually reduce dosage of dosulepine to a maximum of 75 mg/day.
  • Day 1: reduce dosage of dosulepine to 50 mg/day.
  • Day 3: reduce dosage of dosulepine to 25 mg/day.
  • Day 7: stop dosulepine
Eenrichtingbord.png Start escitalopram
  • Day 8: start administration of escitalopram in a normal dosage of 10 mg/day.
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Escitalopram is a weak inhibitor of CYP2D6, which metabolizes dosulepine.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.